Ignite Creation Date:
2024-05-06 @ 9:40 AM
Last Modification Date:
2024-10-26 @ 12:18 PM
Study NCT ID:
NCT03042611
Status:
COMPLETED
Last Update Posted:
2022-07-08
First Post:
2017-01-24
Brief Title:
A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
Sponsor:
Elevar Therapeutics
Organization:
Elevar Therapeutics
Study Overview
Official Title:
A Prospective Randomized Double-Blinded Placebo-Controlled Multinational Multicenter Parallel-group Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care BSC Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer
Status:
COMPLETED
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ANGEL
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care BSC compared to placebo plus BSC in participants with advanced or metastatic gastric cancer GC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None